对卡铂过敏的卵巢癌患者可安全使用顺铂
该研究回顾性分析了2007年1月至2016年5月在意大利那不勒斯国家肿瘤研究所接受卡铂再治疗的铂敏感复发性卵巢癌患者,183例中49例(26.8%)出现卡铂过敏反应,其中37例(77%)后续改用顺铂再挑战,仅5例(13.1%)出现轻度过敏反应且均成功处理,结论认为顺铂再挑战是可行方法。
要点
- 铂敏感复发性卵巢癌卡铂再治疗患者中26.8%(49/183)出现过敏反应。
- 有卡铂过敏史者改用顺铂再挑战,13.1%(5/37)出现轻度过敏且均成功处理。
- 无卡铂过敏但因其他过敏使用顺铂者,过敏反应发生率为7.1%(1/14)。
核心结论
- 对卡铂出现过敏反应的患者,顺铂再挑战是可行方法,可在维持铂类获益的同时降低过敏相关风险。
研究设计与样本
- 回顾性研究,纳入2007年1月至2016年5月在意大利那不勒斯国家肿瘤研究所接受卡铂再治疗的铂敏感复发性卵巢癌患者,共183例。
主要发现
- 183例中49例(26.8%)出现卡铂过敏反应,主要发生在二线治疗期间,过敏前平均化疗周期数为8个(范围3-17)。
- 卡铂过敏反应分级为G2、G3、G4者分别占83%、15%、2%。
- 多因素分析纳入年龄、组织学类型、BRCA状态、既往已知过敏史及联合用药,仅二线卡铂双药方案类型显著影响过敏反应发生,PLD(聚乙二醇脂质体多柔比星)具保护作用(P=0.014,OR=0.027)。
- 37例有卡铂过敏史者接受顺铂再挑战,治疗总体耐受良好,5例(13.1%)出现轻度顺铂过敏反应,均成功处理。
- 14例无卡铂相关过敏但因其他过敏使用顺铂,其中仅1例(7.1%)出现过敏反应。
临床怎么用
- 对有卡铂过敏反应的铂敏感复发性卵巢癌患者,可考虑使用顺铂再挑战以继续铂类治疗(作者结论)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hypersensitivity reactions (HSR) are frequently reported in patients rechallenged with carboplatin for recurrent ovarian cancer (ROC) and represent a critical issue, since discontinuation of the platinum-based therapy could affect prognosis. Several strategies to allow platinum rechallenge have been described, with controversial outcomes. The aim of this study is to illustrate a 10-year experience with cisplatin in patients with a previous HSR to carboplatin or at risk for allergy. METHODS: A retrospective review of all patients with platinum sensitive ROC retreated with carboplatin was performed between January 2007 and May 2016 at the Istituto Nazionale Tumori, Fondazione "G. Pascale", Naples. RESULTS: Among 183 patients, 49 (26.8%) presented HSR to carboplatin, mainly during second line therapy. Mean number of cycles before HSR was 8 (range 3-17). G2, G3 and G4 reaction were detected in 83%, 15% and 2% of patients, respectively. In a multivariate analysis including age, hystotype, BRCA status, previous known HSR, and combination drug administered, only the type of carboplatin-based doublet used as 2nd line therapy was found to significantly affect HSR development, with a protective effect of PLD (pegylated liposomal doxorubicin) (p = 0.014, OR = 0.027). Thirty seven patients (77%) with a previous HSR to carboplatin were rechallenged with cisplatin. Treatment was generally well tolerated. 5 patients (13.1%) experienced mild HSR to cisplatin, successfully managed in all cases. 14 patients were treated with cisplatin even without a carboplatin-related HSR due to other allergies. Among these, only one developed HSR (7.1%). CONCLUSIONS: Cisplatin rechallenge is a feasible approach in patients experiencing HSR to carboplatin to maintain the beneficial effect of platinum while reducing hypersensitivity-related risks.
引用
- Bergamini A, Pisano C, Di Napoli M, et al. Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin. Gynecol Oncol. 2016. PMID: 28094039. doi:10.1016/j.ygyno.2016.10.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。